Compare LOB & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LOB | ADMA |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2014 | 2012 |
| Metric | LOB | ADMA |
|---|---|---|
| Price | $42.36 | $8.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $43.00 | $25.67 |
| AVG Volume (30 Days) | 259.6K | ★ 3.0M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | ★ 31.95 | N/A |
| EPS | ★ 0.60 | 0.19 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | $35.52 | $27.46 |
| Revenue Next Year | $16.03 | $22.11 |
| P/E Ratio | $71.08 | ★ $44.05 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $29.36 | $7.21 |
| 52 Week High | $43.85 | $20.46 |
| Indicator | LOB | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 58.52 | 38.31 |
| Support Level | $39.64 | $8.23 |
| Resistance Level | $42.56 | $8.97 |
| Average True Range (ATR) | 1.04 | 0.26 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 65.50 | 8.58 |
Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.